Linear IgA bullous dermatosis

Meet the patient

A 68-year-old man, ten days into vancomycin for a prosthetic hip infection, breaks out in tense blisters on annular urticarial plaques across his lower trunk and groin. Cluster the new vesicles around the advancing edge of each plaque and you have the 'string of pearls' — the bedside signature of linear IgA disease.[3][7]

Now picture the other face: a three-year-old, systemically well, with a ring of tense blisters encircling the genitals and lower mouth — the 'ring of jewels' of chronic bullous disease of childhood. Same IgA line on DIF, diametrically opposite cause. Hold those two vignettes and the whole topic is yours.[5][8]

Why LABD earns a chapter of its own

It is the only major blistering disorder mediated by IgA, not IgG — and that single fact explains everything that makes LABD distinctive. IgA is a ferocious neutrophil recruiter, so the histology is neutrophil-rich and the disease melts away on dapsone, which cripples neutrophils. That is why LABD behaves nothing like the corticosteroid-dependent pemphigoids beside it.[1][6]

LABD is also a chameleon: it mimics bullous pemphigoid, dermatitis herpetiformis, erythema multiforme, and even toxic epidermal necrolysis, so the diagnosis rests on the immunofluorescence pattern, never on inspection. And it is frequently drug-induced — most often by vancomycin — which transforms management from lifelong immunosuppression into a single chart review and a drug stop.[4][9]

Etymology for viva gold: the 'ring of jewels' and 'string of pearls' are the same phenomenon seen at different ages — centrifugal spread depositing fresh tense vesicles around an older plaque's edge. Two names, one mechanism.[1]

Adult versus child — the two faces

LABD splits cleanly on the age of onset, and the split dictates everything downstream — the likely cause, the distribution, and the prognosis.[1]

The classic trap: the two faces look different but share the identical IgA line on DIF. A child with the 'ring of jewels' is not a different disease from the adult with vancomycin blisters — only the trigger and the age differ.[5]

The mantra for LABD: linear on DIF, vancomycin on the chart, dapsone after G6PD.[1]

How common, and who

LABD is the rarest of the major autoimmune blistering diseases — well below bullous pemphigoid and pemphigus vulgaris. Incidence clusters around 0.2 to 1.0 per million per year, with a roughly equal sex distribution and two age peaks that mirror the two clinical faces.[7]

The pharmacological risk is the one that pays the rent: drug exposure, with vancomycin the canonical answer. The systemic strand is lymphoproliferative malignancy (B-cell lymphoma, CLL, myeloma), ulcerative colitis, and increasingly immune checkpoint inhibitors. An idiopathic or atypical adult case warrants a targeted malignancy screen.[3][6]

Why vancomycin — and the drug list that catches candidates

Vancomycin is the single most common drug cause of LABD and the answer every examiner wants. The presumed mechanism is hapten-driven: the drug binds basement-membrane components to form a neoantigen that elicits an IgA response. The latency is one to two weeks (range 1 to 15 days), and the eruption resolves within two to six weeks of withdrawal.[3][7]

When vancomycin is not on the chart, run the rest of the list:[6]

Everyone forgets: the hospitalised patient's vancomycin for a line infection or surgical prophylaxis is easily missed — read the drug chart and pharmacy record directly, do not just ask.[6]

The IgA line — and why neutrophils explain everything

LABD is an organ-specific autoimmune disease driven by pathogenic IgA autoantibodies against the hemidesmosome adhesion complex. The diagnostic sine qua non is the continuous linear band of IgA along the basement membrane zone on DIF — antibody bound to distributed antigens (BP180 ectodomain, the 97 kDa antigen), not the granular papillary-tip immune complexes of dermatitis herpetiformis.[2]

IgA is unique among immunoglobulins as a potent neutrophil activator through Fc-alpha receptors. Antibody deposition recruits neutrophils to the basement membrane zone; they release elastase, gelatinase, and reactive oxygen species that cleave the lamina lucida. The result is a subepidermal neutrophil-rich blister — and the biological reason LABD responds so dramatically to dapsone, which cripples neutrophil chemotaxis and the respiratory burst.[2][6]

The dominant target antigens overlap with bullous pemphigoid — BP180 (collagen XVII), its shed 120 kDa ectodomain (the 97 kDa LABD antigen), and the NC16A immunodominant domain — but here they are recognised by IgA, not IgG. A minority of sera label the dermal floor on salt-split skin (anti-type VII collagen), an EBA-overlap phenotype that is more dapsone-resistant.[2]

What you see at the bedside

Adult LABD presents with tense, fluid-filled bullae on normal or urticarial, annular or polycyclic plaques — lower trunk, groin, flexures, proximal limbs. The signature is the 'string of pearls': new small tense blisters arranged in an arc around the advancing edge of a plaque, reflecting centrifugal spread. Pruritus ranges from mild to intense; mucosa is involved in roughly half of adults, most often oral and conjunctival.[3][7]

Childhood LABD (CBDC) mirrors the morphology but flips the distribution: tense bullae in annular clusters around the genitals, perineum, perioral face, buttocks, and lower abdomen — the 'ring of jewels' (also 'cluster of jewels' or 'string of beads'). Children are usually systemically well apart from itch and discomfort.[5]

The danger list — what must not be missed: any patient with new blistering and conjunctival involvement needs same-day ophthalmology — symblepharon and synechiae can permanently blind. Severe mucosal disease mimics mucous membrane pemphigoid. Drug-induced LABD in the ICU can erupt like toxic epidermal necrolysis in a patient on vancomycin.[3]

The face-off — LABD against its blistering cousins

Every suspected LABD sits inside the subepidermal blistering differential, and the discriminator is the immunofluorescence pattern, not the clinical look.[2]

The one-line discriminator: linear IgA = LABD; granular IgA in papillae = DH; linear IgG/C3 = BP or EBA. Salt-split then separates the IgG diseases — roof for BP and LABD, floor for EBA. Clinical context refines it: coeliac disease points to DH, advanced age to BP, pregnancy to pemphigoid gestationis, trauma-prone scarring to EBA.[2]

Confirm it on immunofluorescence — never on inspection

The diagnosis of LABD is immunopathological. Four investigations work together; none can be omitted in a definitive work-up.[1][2]

Histology of an early intact blister shows a subepidermal blister with a predominantly neutrophilic infiltrate clustering along the papillary tips. The pattern overlaps with DH, but DIF settles it. A predominantly eosinophilic infiltrate points to bullous pemphigoid instead.[2]

Direct immunofluorescence is the diagnostic test. Biopsy perilesional skin within 1 cm of an active lesion, submitted in Michel's medium or saline — never formalin. The finding is a continuous homogeneous LINEAR band of IgA along the BMZ. That single line confirms LABD, distinguishes it from DH (granular) and BP (linear IgG/C3), and occasionally shows concomitant IgG or C3 in a mixed-deposition subset.[1][2]

Indirect immunofluorescence on 1 M NaCl salt-split skin localises the antibody: in most LABD cases IgA labels the epidermal roof (the 97 kDa antigen lies in the lamina lucida). A minority label the dermal floor — an EBA-overlap phenotype that is more dapsone-resistant.[2]

IgA anti-BP180 NC16A ELISA is positive in a substantial proportion, reflecting the shared BP180 target; the IgA (not IgG) reactivity distinguishes LABD from BP and titres fall with treatment.[2]

The pre-dapsone checklist — do not skip it

Before the first dapsone tablet, several blood tests are mandatory, and the G6PD check is the one that prevents harm.[6]

Stop the drug, then reach for dapsone

The single most important sentence in LABD management: drug-induced disease is treated by drug withdrawal; idiopathic disease is treated by dapsone. Conflating the two — parking a vancomycin-induced patient on lifelong dapsone — is avoidable toxicity.[7]

Dapsone produces a response so rapid — within 24 to 72 hours — that it is itself a diagnostic clue when DIF is pending. Start at 50 mg once daily in adults, titrate to a typical 100 to 150 mg daily; children receive 0.5 to 2 mg/kg/day. Counsel the patient on haemolysis (pallor, fatigue, jaundice) and methaemoglobinaemia (cyanosis, breathlessness, headache), and watch for the dapsone hypersensitivity syndrome that appears at two to eight weeks.[6]

When dapsone cannot be used or falls short, the ladder is colchicine, sulfasalazine or sulfapyridine (useful in G6PD-deficient patients), short-course prednisolone, and steroid-sparing immunosuppressants; rituximab and IVIG are reserved for refractory or mucosal-dominant disease.[1]

The scenarios that change the plan

Vancomycin-induced LABD. Withdrawal is the single most effective intervention; bridging dapsone or potent topical corticosteroids control symptoms while lesions resolve over two to six weeks. Re-challenge is expected to relapse — avoid it.[3][7]

Chronic bullous disease of childhood. Dapsone 0.5 to 2 mg/kg/day after the G6PD check is first-line, with colchicine or short-course prednisolone as alternatives. Most children remit before puberty, so the aim is symptomatic control with the least toxic regimen.[5][8]

Mucosal-dominant and ocular LABD. Predominantly oral, conjunctival, or genital erosions mimic mucous membrane pemphigoid and carry the same risk of ocular scarring. Any conjunctival involvement needs same-day ophthalmology, topical lubricants and corticosteroids, and aggressive systemic therapy — dapsone alone is often insufficient here.[3]

Pregnancy-associated LABD overlaps with pemphigoid gestationis; DIF distinguishes them (linear IgA in LABD versus linear C3 or IgG in PG). Dapsone after the G6PD check is preferred; there is a risk of transient neonatal blistering from transplacental IgA.[6]

Paraneoplastic and checkpoint-inhibitor LABD. Lymphoproliferative disease (B-cell lymphoma, CLL, myeloma) is the most consistent neoplastic association; screen an idiopathic or atypical adult case with FBC, film, LDH, and electrophoresis. Checkpoint-inhibitor LABD sits within the broader immune-related adverse-event spectrum.[3]

Complications and the three classic errors

Complications arise from the disease (mucosal scarring, secondary infection, fluid loss), from misdiagnosis, and from dapsone itself.[1]

Prognosis — follow the cause

The prognosis of LABD is generally favourable and tracks the aetiology. Drug-induced disease resolves within two to six weeks of withdrawal and needs no maintenance. Idiopathic adult disease is chronic and relapsing-remitting, with spontaneous remission in roughly 30 to 50 per cent within three to six years. Childhood LABD remits before puberty in most, within two to five years.[1][7]

Disposition is outpatient for most; admit for extensive skin failure, severe mucosal (especially ocular) disease, systemic upset, or diagnostic uncertainty in a sick patient. Ophthalmology follow-up is essential for any ocular involvement.[5][8]

Ward-round test